- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT03098186
TXT2HEART COLOMBIA: Evaluation of the Efficacy and Safety of Text Messages to Improve Adherence to Cardiovascular Medications in Secondary Prevention
Purpose of the trial: To evaluate the efficacy and safety of an intervention with SMS messages delivered by mobiles phones to improve adherence to cardiovascular medications in patients with atherosclerotic cardiovascular disease (ASCVD).
Trial design: Two-parallel arm, single-blind, individually randomized controlled trial.
Primary endpoint: Differences in changes (baseline minus 12 months) of: Low density lipoprotein cholesterol (LDL-C), Systolic Blood pressure and Heart Rate.
Secondary endpoints: Differences in the changes (baseline minus 12-months) of: (i) adherence to cardiovascular medications used in secondary prevention measured by MARS-5 questionnaire; and (ii) Urinary levels of 11 dh-TxB2, Rates of composite end-point of cardiovascular death and hospitalization due to cardiovascular disease up to 12 months, Rates of composite of non-cardiovascular death or hospitalizations due to non-cardiovascular disease up to 12 months and Adverse events: traffic accidents and injuries while reading SMS related to the trial.
Duration of follow-up: 12 months
Trial treatment:
Intervention: The active treatment will consist of SMS that are aimed to modified behavioral factors associated with poor adherence to cardiovascular medications used in secondary prevention. The SMS will be delivered daily during the first month, increasing one day of interval for each week during the second month, and weekly thereafter until end of month 12th. In addition, they will receive SMS thanking for their participation in the trial, reminders of trial appointment and informing if they have changed contact details. The frequency of this SMS will be monthly.
Control: participants will only receive the SMS thanking for their participation in the trial, reminders of trial appointment and informing if they have changed contact details. The frequency of this SMS will be monthly.
Expected sample size, enrollment and expected number of centers:
Sample size = 1600 Recruitment start date: March , 2017 Recruitment end date: September, 2017 Follow-up end date: March, 2018 Number of centers: 1
Statistical considerations:
- Intention to treat analysis
- The trial has >90% power (2 sided alpha= 0.05) to detect a reduction in LDL-C as low as 5.1 mg/dl, under the assumption that SMS will increase adherence to statins by 7%.
- The primary outcomes will be analyzed using ANCOVA.
Partially Financed by COLCIENCIAS Code: 656672553352
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
Santander
-
Floridablanca, Santander, Colombia, 683071
- Fundación Cardiovascular de Colombia
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Age ≥18 years old
History of at least one of the following arterial occlusive events:
- acute coronary syndrome (unstable angina, acute myocardial infarction with or without ST elevation),
- stable angina,
- ischemic cerebrovascular disease,
- peripheral arterial disease or
- coronary revascularization (coronary artery bypass surgery (CABG) or percutaneous transluminal coronary angioplasty (PTCA).
- Own at least one mobile phone
- Ability to read and understand text messages (SMS)
- Intention to stay in the country of recruitment during the next 12 months
Exclusion Criteria:
- Contraindication to take all cardiovascular medications used in secondary prevention.
- Participation in another randomized clinical trial that could interfere with adherence to treatment.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Stödjande vård
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Trippel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: Intervention SMS
|
The active treatment will consist of SMS that are aimed to modified behavioral factors associated with poor adherence to cardiovascular medications used in secondary prevention.
The SMS will be delivered daily during the first month, increasing one day of interval for each week during the second month , and weekly thereafter until end of month 12th.
In addition, they will receive SMS thanking for their participation in the trial, reminders of trial appointment and informing if they have changed contact details.
The frequency of this SMS will be monthly.
|
Placebo-jämförare: Control SMS
SMS to thanks for participation in the trial and reminders of trial appointments.
|
Participants will only receive the SMS thanking for their participation in the trial, reminders of trial appointment and informing if they have changed contact details.
The frequency of this SMS will be monthly.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Differences in physiological variables depending on taking medications: low density lipoprotein cholesterol
Tidsram: Baseline and 12 months
|
Low density lipoprotein cholesterol (LDL-C) mg/dl
|
Baseline and 12 months
|
Differences in physiological variables depending on taking medications: Systolic Blood pressure
Tidsram: Baseline and 12 months
|
Systolic Blood pressure mmHg
|
Baseline and 12 months
|
Differences in physiological variables depending on taking medications: Heart Rate
Tidsram: Baseline and 12 months
|
Heart Rate: Heartbeats per minute
|
Baseline and 12 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Changes in self-reported adherence and recurrence of new cardiovascular and adverse events.
Tidsram: Baseline and 12 months
|
Adherence to cardiovascular medications used in secondary prevention measured by MARS-5 questionnaire
|
Baseline and 12 months
|
Urinary levels of 11 dh-TxB2
Tidsram: Baseline and 12 months
|
Changes in Urinary levels of 11 dh-TxB2 pg/dl
|
Baseline and 12 months
|
Death due to cardiovascular disease
Tidsram: Baseline and 12 months
|
Rate of death due to cardiovascular disease.
|
Baseline and 12 months
|
Hospitalization due to cardiovascular disease
Tidsram: Baseline and 12 months
|
Rate of hospitalization due to cardiovascular disease.
|
Baseline and 12 months
|
Death due to non-cardiovascular disease
Tidsram: Baseline and 12 months
|
Rate of death due to non-cardiovascular disease.
|
Baseline and 12 months
|
Hospitalization due to non-cardiovascular disease
Tidsram: Baseline and 12 months
|
Rate of hospitalizations due to non-cardiovascular disease.
|
Baseline and 12 months
|
Adverse events
Tidsram: Baseline and 12 months
|
Traffic accidents and injuries while reading SMS related to the trial.
(Percentage)
|
Baseline and 12 months
|
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Studiestol: Juan P Casas, PhD, University College, London
- Studiestol: Pablo A Perel, PhD, London School of Hygiene and Tropical Medicine
- Studierektor: Norma C Serrano, MsC, Fundación Cardiovascular de Colombia
- Huvudutredare: Anderson Bermon, MsC, Fundación Cardiovascular de Colombia
- Huvudutredare: Ana F Uribe, PhD, Universidad Pontificia Bolivariana
Publikationer och användbara länkar
Allmänna publikationer
- Bermon A, Uribe AF, Perez-Rivero PF, Prieto-Merino D, Saaibi JF, Silva FA, Canon DI, Castillo-Gonzalez KM, Caceres-Rivera DI, Guio E, Meneses-Castillo KJ, Castillo-Meza A, Atkins L, Horne R, Murray E, Serrano NC, Free C, Casas JP, Perel P. Efficacy and Safety of Text Messages Targeting Adherence to Cardiovascular Medications in Secondary Prevention: TXT2HEART Colombia Randomized Controlled Trial. JMIR Mhealth Uhealth. 2021 Jul 28;9(7):e25548. doi: 10.2196/25548.
- Bermon A, Uribe-Rodriguez AF, Perez-Rivero PF, Prieto-Merino D, Caceres Rivera DI, Guio E, Atkins L, Horne R, Murray E, Serrano Diaz NC, Free C, Perel P, Casas JP. Evaluation of the efficacy and safety of text messages targeting adherence to cardiovascular medications in secondary prevention: the txt2heart Colombia randomised controlled trial protocol. BMJ Open. 2019 Dec 8;9(12):e028017. doi: 10.1136/bmjopen-2018-028017.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 416
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Intervention SMS
-
Centre for Addiction and Mental HealthCanadian Institutes of Health Research (CIHR); Institute for Clinical Evaluative...RekryteringSchizofreni | Schizofrenispektrum och andra psykotiska störningar | Schizoaffektiv sjukdom | Bipolär sjukdom | Psykos | Schizofreniforma sjukdomar | Substansinducerade psykoser | Psykotiskt avsnitt | Första avsnittet Psykos | Psykoser, Affektiva | Depressiv psykosKanada
-
University of RochesterNational Cancer Institute (NCI)AvslutadLivmoderhalscancerFörenta staterna
-
University of PennsylvaniaAvslutadKoloskopi | Följsamhet, tålmodig | SMSFörenta staterna
-
St. Louis UniversityEpharmix, Inc.AvslutadKorttarmssyndromFörenta staterna
-
Harvard Medical School (HMS and HSDM)Partners in HealthAktiv, inte rekryterandeCovid-19 | Mental hälsa | DesinformationHaiti, Malawi, Rwanda
-
VA Office of Research and DevelopmentHar inte rekryterat ännuKronisk obstruktiv lungsjukdomFörenta staterna
-
City of Hope Medical CenterNational Cancer Institute (NCI)Rekrytering
-
George Washington UniversityNYU Langone HealthRekrytering
-
Addis Ababa UniversityFogarty International Center of the National Institute of HealthOkändTuberkulos | UndernäringEtiopien
-
NYU Langone HealthAvslutadDiabetes typ 2Förenta staterna